Dr Reddy's Q1 net profit falls 69% to Rs 443 crore on semaglutide inventory costs

Dr Reddy's Q1 net profit fell 69% to Rs 443 crore.

Decline is attributed to costs from building safety stock of semaglutide inventory.

The company reported inventory charges related to semaglutide, a drug for diabetes and weight loss.